Aprogen Pharmaceuticals Inc (003060) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Aprogen Pharmaceuticals Inc KRW 4,917, price KRW 1,639, upside +200.0%, quality 22 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Aprogen Pharmaceuticals Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 1,599 KRW – 153,318 KRW · fair‑value band 3,669 KRW – 7,339 KRW · the 1,639 KRW price screens below the 4,917 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Aprogen Pharmaceuticals in your weekly email
Every Wednesday you see whether Aprogen Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Aprogen Biologics Inc. manufactures and sells pharmaceutical products primarily in South Korea. The company was founded in 1960 and is headquartered in Seoul, South Korea.
Stock analysis
Aprogen Pharmaceuticals Inc (003060) currently trades at 1,639 KRW, while our model-based Fair Value estimate is 4,917 KRW, implying the stock looks roughly 66.7% undervalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 80/100, which puts the evidence level at low.
Scenario range: 3,669 KRW (bear) to 7,339 KRW (bull), the price of 1,639 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 22/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Aprogen Pharmaceuticals Inc reported revenue of 73.2B KRW in FY2025 versus 56.5B KRW in FY2021, a compound +6.7%/yr. Reported net income was −170B KRW in FY2025.
Key figures
Market cap 26.1B KRW (≈ $19.2M) · P/S ratio 0.33 · Net margin −168% · Return on equity −42.8% · Return on assets (EBIT) −6.1% · Operating margin −74.1% · Revenue (TTM) 78.0B KRW · Revenue growth (YoY) +28.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (low confidence).
What moves the price
The share trades about 83% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at 200%, 003060 screens cheaper than that median.
Fair Value models
Bear 3,669 KRWFair Value 4,917 KRWBull 7,339 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.27/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+8.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.6%
Start year 2020 (pandemic). Over 10 years: +6.1% a year
Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.0%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1.8% (2020) → −82.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Aprogen Pharmaceuticals Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 629 stocks
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Aprogen Pharmaceuticals Inc (003060) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 4,917 KRW versus a price of 1,639 KRW, about +200% upside (undervalued).
What is the fair value of 003060?
Our model-based fair value for Aprogen Pharmaceuticals Inc is 4,917 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 1,639 KRW.
What is the quality score of 003060?
Aprogen Pharmaceuticals Inc has a Quality Score of 22/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Aprogen Pharmaceuticals Inc (003060)?
Our model-based price target is the fair value of 4,917 KRW (as of Sep 24, 2026) from 1 valuation models. Cautious scenario 3,669 KRW, optimistic scenario 7,339 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Aprogen Pharmaceuticals Inc stock forecast for 2026?
Our models put fair value at 4,917 KRW, about +200% upside versus a price of 1,639 KRW (undervalued). Cautious scenario 3,669 KRW, optimistic scenario 7,339 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Aprogen Pharmaceuticals Inc (003060)?
Aprogen Pharmaceuticals Inc reported trailing-twelve-month revenue of about 78.0B KRW (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Aprogen Pharmaceuticals Inc (003060)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Aprogen Pharmaceuticals Inc it is 4,917 KRW per share (as of Sep 24, 2026), against a price of 1,639 KRW. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Aprogen Pharmaceuticals Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 003060 trades below its calculated fair value: price 1,639 KRW, fair value 4,917 KRW, a gap of about +200% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 003060?
No. The price is what the market pays today (1,639 KRW); the fair value is what the company's own numbers justify (4,917 KRW). For Aprogen Pharmaceuticals Inc the two are 3,278 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Aprogen Pharmaceuticals Inc worth?
The market values Aprogen Pharmaceuticals Inc at about 26.1B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 1,639 KRW; our models calculate a fair value of 4,917 KRW per share.
What do the bullish and bearish scenarios say about 003060?
Our models span a range for Aprogen Pharmaceuticals Inc: cautious scenario 3,669 KRW, base 4,917 KRW, optimistic 7,339 KRW per share (as of Sep 24, 2026, price 1,639 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Aprogen Pharmaceuticals Inc (003060)?
Balance-sheet figures for Aprogen Pharmaceuticals Inc (as of Sep 24, 2026): return on equity −42.8%, debt of 0.19 per unit of equity. They feed the Quality Score of 22/100, which measures business quality independently of the share price.
How far is 003060 from its 52-week high?
Aprogen Pharmaceuticals Inc trades at 1,639 KRW, about 83% below its 52-week high of 9,660 KRW and 3% above the low of 1,599 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 4,917 KRW is for.
Which stocks are comparable to Aprogen Pharmaceuticals Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Aprogen Pharmaceuticals Inc stock attractive at the current price?
The data as of Sep 24, 2026: price 1,639 KRW, calculated fair value 4,917 KRW (+200%), Quality Score 22/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 003060 calculated?
We run Aprogen Pharmaceuticals Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 4,917 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Aprogen Pharmaceuticals Inc currently trades 200 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Aprogen Pharmaceuticals Inc (003060)?
The closing price on Sep 23, 2026 was 1,639 KRW. Our model-based fair value is 4,917 KRW, about +200% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Aprogen Pharmaceuticals Inc right now?
The large discount to fair value meets weak quality (22/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (3,669 KRW). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (3,669 KRW to 7,339 KRW) leaves room in how you read the outcome.
Key figures of Aprogen Pharmaceuticals Inc
How large is the market capitalisation of Aprogen Pharmaceuticals Inc (003060)?
The market capitalisation of Aprogen Pharmaceuticals Inc is 26.1B KRW (≈ $19.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Aprogen Pharmaceuticals Inc (003060)?
The price-to-sales ratio of Aprogen Pharmaceuticals Inc is 0.33 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Aprogen Pharmaceuticals Inc (003060)?
The net margin of Aprogen Pharmaceuticals Inc is −168% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Aprogen Pharmaceuticals Inc (003060)?
The return on equity (ROE) of Aprogen Pharmaceuticals Inc is −42.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Aprogen Pharmaceuticals Inc (003060)?
On an EBIT basis the return on assets of Aprogen Pharmaceuticals Inc is −6.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Aprogen Pharmaceuticals Inc (003060)?
The operating margin of Aprogen Pharmaceuticals Inc is −74.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Aprogen Pharmaceuticals Inc (003060)?
Revenue at Aprogen Pharmaceuticals Inc is growing +28.3% versus a year earlier (3y avg +4.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Aprogen Pharmaceuticals Inc (003060)?
Earnings per share at Aprogen Pharmaceuticals Inc are growing −72.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Aprogen Pharmaceuticals Inc (003060) generate?
The free cash flow of Aprogen Pharmaceuticals Inc is −48.0B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Aprogen Pharmaceuticals Inc (003060) carry?
The net debt of Aprogen Pharmaceuticals Inc is 183B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Aprogen Pharmaceuticals Inc in the live analysis
One click puts Aprogen Pharmaceuticals Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
